G I-150 (Ibandronate sodium 150 mg (base))
Pill imprint G I-150 has been identified as Ibandronate sodium 150 mg (base).
Ibandronate is used in the treatment of prevention of osteoporosis; osteoporosis and belongs to the drug class bisphosphonates. Risk cannot be ruled out during pregnancy. Ibandronate 150 mg (base) is not a controlled substance under the Controlled Substance Act (CSA).
Ibandronate sodium
- Imprint:
- G I-150
- Strength:
- 150 mg (base)
- Color:
- White
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- Bisphosphonates
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Mylan Pharmaceuticals Inc.
- National Drug Code (NDC):
- 00378-5215
- Inactive Ingredients:
- ammonia
ferrosoferric oxide
silicon dioxide
crospovidone
hydroxypropyl cellulose
lactose monohydrate
magnesium stearate
microcrystalline cellulose
polyethylene glycol
povidone
shellac
titanium dioxide
More about ibandronate
Consumer resources
- Ibandronate
- Ibandronate oral/injection
- Ibandronate Intravenous (Advanced Reading)
- Ibandronate Oral, Injection (Advanced Reading)
- Other brands: Boniva
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
